Clinical Trial

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

Study acronym: DECIST
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 25, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2019-11-06; most recent amendment 2025-05-21.
Status change: Active, Not Recruiting → Recruiting 2025-05-19
Status change: Recruiting → Active, Not Recruiting 2024-09-27
Status change: Not Yet Recruiting → Recruiting 2020-08-03
Trial Details
NCT Number NCT04157127
Lead Sponsor Diakonos Oncology Corporation
Collaborators: Baylor College of Medicine
Conditions Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenosquamous Carcinoma
Enrollment 18 participants
Start Date 2020-08-03
Primary Completion 2026-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-25